Biotech's Next Big Thing: ASCO
TheStreet Sr. Columnst Adam Feuerstein previews the research abstracts presented next week in advance of June's ASCO cancer event.
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback;
to send him an email.
